“The Global Attention Deficit Hyperactivity Disorder Therapeutics (ADHD) Market was valued around US$ XX Mn by 2018 and growing at a prominent growth rate over the forecast years 2019-2025 to reach US$ US$ 22,736.4 Mn by 2025 owing to grow in R&D for the development of newer drugs”
The global attention deficit hyperactivity disorder therapeutics market was valued at US$ XX Mn in 2018 and increasing at a prominent growth rate over the forecast years due to increase in the prevalence of ADHD prevalence in children with 4-17 years age around the globe. Moreover, increase in the R&D expenditure for the development of newer therapeutics, pipeline drugs under various stages of clinical trials, and favorable reimbursement guidelines are expected to propel the global attention deficit hyperactivity disorder therapeutics market over the forecast years. For instance, in October 2018, Dr. Reddy’s Laboratories launched Atomexitine in U.S. for the patients with ADHD. However, stringent regulations for the product approval, development of medical devices for ADHD treatment, and lack of disease awareness in the underdeveloped countries are hamper the growth of attention deficit hyperactivity disorder therapeutics market over the forecast timeframe
Global attention deficit hyperactivity disorder (ADHD) therapeutics market segmented on the basis of drug class, age group, distribution channel, and region
Avail Sample Report of the Market @ https://www.precisionbusinessinsights.com/request-sample?product_id=15789
Dopamine Agonists Dominate the Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market
Based on the drug class, global attention deficit hyperactivity disorder therapeutics market segmented into stimulants and non-stimulants. Stimulants dominated the global attention deficit hyperactivity disorder therapeutics market in 2018 and the segmented expected to contribute a major share in 2025 owing to increase in the adoption of stimulants over non-stimulants among the physicians. Stimulants are effective in the treatment of ADHD symptoms, various drugs under clinical studies, and FDA approval for the stimulants are burgeon the revenue of segment. For instance, in April 2016, Tris Pharma received the FDA approval and launched Dynavel XR (Amphetamine), for the treatment of ADHD disorders in patients with over 6 years age.
North America Leads the Global Attention Deficit Hyperactivity Disorder Therapeutics (ADHD) market
PBI’s global attention deficit hyperactivity disorder therapeutics market report analyses the market in different regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. According to regional analysis, North America accounted for larger revenue share through 2014-2018 and expected to dominate over 2019-2025 owing to surge in the prevalence of ADHD in U.S. and Canada. For instance, according to American Psychiatric Association, approximately 5% of children living with ADHD in United States. Moreover, favorable reimbursement policies and increase in the R&D activities for the development of newer therapeutics are bolster the market over the forecast years. Europe attention deficit hyperactivity disorder therapeutics market projected to exhibit significant growth due to adoption of novel molecules and surge in healthcare expenditure in the region.
Launch of newer products, frequent product approvals, and strategic alliances are the key strategies adopted by market players
Global attention deficit hyperactivity disorder therapeutics market further reveals that the key players increasingly adopting strategies such as launch of newer products, frequent product approvals, and long term alliance to improve market revenue share and gaining significant geographic presence across the region. For instance, in June 2017, Shire plc received the USFDA approval for Mydayis, a long acting ADHD drug for adolescents and adults
Key player’s profiles in the report are Johnson and Johnson Services, Inc., Pfizer, Inc., Eli Lilly and Co., Shire plc, Dr. Reddy’s Laboratories, GlaxoSmithKline plc, Novartis AG, Purdue Pharma L.P., NEOS Therapeutics, Inc., and Takeda Pharmaceuticals Co., Ltd.
Precision Business Insights (PBI) in its report titled “Global Attention Deficit Hyperactivity Disorder Therapeutics Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2014-2018 and Forecast 2019-2025” assesses the market performance over seven years forecast period over 2019-2025. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period.
By Drug Class
By Age Group
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Rest of Europe
- Australia & New Zealand
- ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
- South Korea
- Rest of Asia-Pacific
- Rest of Latin America
Middle East and Africa (MEA)
- Gulf Cooperation Council (GCC) Countries
- South Africa
- Rest of MEA
Precision Business Insights is one of the leading market research and management consulting firm, run by a group of seasoned and highly dynamic market research professionals with a strong zeal to offer high-quality insights.
Senior Business Development Executive
Email @ email@example.com
Call @ +1-866-598-1553
Precision Business Insights